| Product Code: ETC7354144 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Greece Neurological Disorder Drugs Market Overview |
3.1 Greece Country Macro Economic Indicators |
3.2 Greece Neurological Disorder Drugs Market Revenues & Volume, 2021 & 2031F |
3.3 Greece Neurological Disorder Drugs Market - Industry Life Cycle |
3.4 Greece Neurological Disorder Drugs Market - Porter's Five Forces |
3.5 Greece Neurological Disorder Drugs Market Revenues & Volume Share, By Indication, 2021 & 2031F |
3.6 Greece Neurological Disorder Drugs Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.7 Greece Neurological Disorder Drugs Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.8 Greece Neurological Disorder Drugs Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
3.9 Greece Neurological Disorder Drugs Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Greece Neurological Disorder Drugs Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of neurological disorders in Greece |
4.2.2 Rising awareness about neurological disorders and available treatments |
4.2.3 Technological advancements in drug development for neurological disorders |
4.3 Market Restraints |
4.3.1 Stringent regulations and approval processes for neurological disorder drugs in Greece |
4.3.2 High cost of neurology medications leading to affordability issues for patients |
5 Greece Neurological Disorder Drugs Market Trends |
6 Greece Neurological Disorder Drugs Market, By Types |
6.1 Greece Neurological Disorder Drugs Market, By Indication |
6.1.1 Overview and Analysis |
6.1.2 Greece Neurological Disorder Drugs Market Revenues & Volume, By Indication, 2021- 2031F |
6.1.3 Greece Neurological Disorder Drugs Market Revenues & Volume, By Epilepsy, 2021- 2031F |
6.1.4 Greece Neurological Disorder Drugs Market Revenues & Volume, By Alzheimers Disease, 2021- 2031F |
6.1.5 Greece Neurological Disorder Drugs Market Revenues & Volume, By Parkinsons Disease, 2021- 2031F |
6.1.6 Greece Neurological Disorder Drugs Market Revenues & Volume, By Multiple Sclerosis, 2021- 2031F |
6.1.7 Greece Neurological Disorder Drugs Market Revenues & Volume, By Cerebrovascular Disease, 2021- 2031F |
6.1.8 Greece Neurological Disorder Drugs Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Greece Neurological Disorder Drugs Market, By Drug Class |
6.2.1 Overview and Analysis |
6.2.2 Greece Neurological Disorder Drugs Market Revenues & Volume, By Cholinesterase Inhibitors, 2021- 2031F |
6.2.3 Greece Neurological Disorder Drugs Market Revenues & Volume, By NMDA Receptor Antagonists, 2021- 2031F |
6.2.4 Greece Neurological Disorder Drugs Market Revenues & Volume, By Antiepileptic, 2021- 2031F |
6.2.5 Greece Neurological Disorder Drugs Market Revenues & Volume, By Antipsychotic and Antidepressant, 2021- 2031F |
6.2.6 Greece Neurological Disorder Drugs Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Greece Neurological Disorder Drugs Market, By Route of Administration |
6.3.1 Overview and Analysis |
6.3.2 Greece Neurological Disorder Drugs Market Revenues & Volume, By Oral, 2021- 2031F |
6.3.3 Greece Neurological Disorder Drugs Market Revenues & Volume, By Parenteral, 2021- 2031F |
6.3.4 Greece Neurological Disorder Drugs Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Greece Neurological Disorder Drugs Market, By End-Users |
6.4.1 Overview and Analysis |
6.4.2 Greece Neurological Disorder Drugs Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 Greece Neurological Disorder Drugs Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.4.4 Greece Neurological Disorder Drugs Market Revenues & Volume, By Homecare, 2021- 2031F |
6.4.5 Greece Neurological Disorder Drugs Market Revenues & Volume, By Others, 2021- 2031F |
6.5 Greece Neurological Disorder Drugs Market, By Distribution Channel |
6.5.1 Overview and Analysis |
6.5.2 Greece Neurological Disorder Drugs Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.5.3 Greece Neurological Disorder Drugs Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.5.4 Greece Neurological Disorder Drugs Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.5.5 Greece Neurological Disorder Drugs Market Revenues & Volume, By Others, 2021- 2031F |
7 Greece Neurological Disorder Drugs Market Import-Export Trade Statistics |
7.1 Greece Neurological Disorder Drugs Market Export to Major Countries |
7.2 Greece Neurological Disorder Drugs Market Imports from Major Countries |
8 Greece Neurological Disorder Drugs Market Key Performance Indicators |
8.1 Number of clinical trials for neurological disorder drugs in Greece |
8.2 Adoption rate of innovative treatments for neurological disorders |
8.3 Investment in research and development for neurological disorder drugs in Greece |
9 Greece Neurological Disorder Drugs Market - Opportunity Assessment |
9.1 Greece Neurological Disorder Drugs Market Opportunity Assessment, By Indication, 2021 & 2031F |
9.2 Greece Neurological Disorder Drugs Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
9.3 Greece Neurological Disorder Drugs Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.4 Greece Neurological Disorder Drugs Market Opportunity Assessment, By End-Users, 2021 & 2031F |
9.5 Greece Neurological Disorder Drugs Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Greece Neurological Disorder Drugs Market - Competitive Landscape |
10.1 Greece Neurological Disorder Drugs Market Revenue Share, By Companies, 2024 |
10.2 Greece Neurological Disorder Drugs Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here